Viral vaccines

Details Viral vaccines Viral vaccines

2008-05-20

2008-05-20

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S199100, C435S235100, C435S236000

Reexamination Certificate

active

07374768

ABSTRACT:
A mutant virus for use as a vaccine for prophylaxis or therapy, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus, e.g. a herpesvirus, e.g HSV-1 or HSV-2, is capable of protecting a susceptible species immunised therewith against infection by the corresponding wild-type virus. In another aspect, the mutant virus acts as a vector for an immunogenic protein derived from a pathogen, encoded by foreign DNA incorporated in the mutant virus. The mutant virus can be produced by a recombinant host cell which expresses a gene complementing the defect. The mutant virus can be infectious for the host to be protected, and the genetic defect can allow expression in the infected host of at least some of the viral genes, which can provoke a cell-mediated immune response. The defect can be in a glycoprotein gene such as gH.

REFERENCES:
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4996152 (1991-02-01), Carter et al.
patent: 5110587 (1992-05-01), Paoletti et al.
patent: 5155020 (1992-10-01), Paoletti
patent: 5166057 (1992-11-01), Palese et al.
patent: 5174993 (1992-12-01), Paoletti
patent: 5204243 (1993-04-01), Paoletti
patent: 5225336 (1993-07-01), Paoletti
patent: 5338683 (1994-08-01), Paoletti
patent: 5364773 (1994-11-01), Paoletti et al.
patent: 5453364 (1995-09-01), Paoletti
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5505941 (1996-04-01), Paoletti
patent: 5583028 (1996-12-01), Paoletti et al.
patent: 5766882 (1998-06-01), Falkner et al.
patent: 5770212 (1998-06-01), Falkner et al.
patent: 0213894 (1987-03-01), None
patent: 0386882 (1990-09-01), None
patent: 0453242 (1991-10-01), None
patent: 0 753 581 (1997-01-01), None
patent: WO 8909271 (1989-10-01), None
patent: WO 9005538 (1990-05-01), None
patent: WO 9010693 (1990-09-01), None
patent: WO 9105055 (1991-04-01), None
patent: 9205263 (1992-04-01), None
patent: WO 94032074 (1994-02-01), None
patent: WO-95/27507 (1995-10-01), None
patent: WO-96/21727 (1996-07-01), None
patent: WO-96/39177 (1996-12-01), None
patent: WO-96/39491 (1996-12-01), None
patent: WO-96/40241 (1996-12-01), None
Ballay A. et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human sesion albamins From recombinant Human adenoviruses The EMBO Journal vol. 4: 3861-3865 (1985).
Alkhatib G. et al. High level eukaryotic In vivo expression of biologically active Meades virushemoglutin by using an adenovirus Type 5 helper-free vector system. J. Virology 62:2718-2727 (1988).
Hutchinson et al. “A Novel Herpes Simplex Virus Glycoprotein, gL, Forms a Complex with Glycoprotein H (gH) and Affects Normal Folding and Surface Expression of gH”. Journal of Virology. vol. 66, No. 4, pp. 2240-2250, Apr. 1992.
Schranz et al. “A Viable HSV-1 Mutant Deleted in Two Nonessential Major Glycoproteins”. Virology. vol. 170, pp. 273-276, 1989.
Haj-Ahmad et al. “Development of a Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene”. Journal of Virology. vol. 57, No. 1, pp. 267-274, Jan. 1986.
Weber et al. “Rapid Identification of Nonessential Genes of Herpes Simplex Virus Type 1 by Tn5 Mutagenesis”. Science. vol. 236, pp. 576-579, May 1, 1987.
Ligas et al. “A Herpes Simplex Virus Mutant in Which Glycoprotein D Sequences Are Replaced by Beta-Galactosidase Sequences Binds to but Is Unable to Penetrate into Cells”. Journal of Virology. vol. 62, No. 5, pp. 1486-1494, May 1986.
Moss, B. 1985. Virology, ed. B. N. Fields et al, Raven Press, NY, pp. 685-703, 1985.
Miner, J/N et al. 1990. Virus Genes, vol. 3:4, pp. 355-359, 1990.
Roizman et al. Herpesviruses and Their Replication. In Virology, ed. B. N. Fields et al, Raven Press, NY, p. 497-526, 1985.
Farrell, H.E., et al., “Vaccine Potential of a Herpes Simplex Virus Type 1 Mutant with an Essential Glycoprotein Deleted”Journal of Virology, 68(2) :927-932 (1994).
Morrison, L.A., et al., “Immunization with Relication-Defective Mutants of Herpes Simplex Virus Type 1: Sites of Immune Intervention in Pathogenesis of Challenge Virus Infection.”Journal of Virology, 68(2) :689-696 (1994).
Peeters, B., et al., “Non-Transmissible Pseudorabies Virus gp50 Mutants: A New Generation of Safe Live Vaccines.”Vaccine, 12(4) :375-380 (1994).
Nguyen, L.H., et al., “Replication-Defective Mutants of Herpes Simplex Virus (HSV) Induce Cellular Immunity and Protect Against Lethal HSV Infection.”Journal of Virology, 66(12) :7067-7072 (1992).
Graham, F.L., et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5.”J. Gen. Virol., 36:59-72 (1977).
Harrison, T., et al., “Host-Range Mutants of Adenovirus Type 5 Defective for Growth in HeLa Cells.”Virology, 77:319-329 (1977).
Gluzman, Y., “SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants.”Cell, 23:175-182 (1981).
Cai, W., et al., “Linker-Insertion Nonsense and Restriction-Site Deletion Mutations of the gB Glycoprotein Gene of Herpes Simplex Virus Type 1.”Journal of Virology, 61(3) :714-721 (1987).
Racaniello, V.R., et al., “Cloned Poliovirus Complementary DNA is Infectious in Mammalian Cells.”Science, 214:916-918 (1981).
Ligas, M.W., et al., “A Herpes Simplex Virus Mutant in which Glycoprotein D Sequences are Replaced by β-Galactosidase Sequences Binds to but is Unable to Penetrate into Cells.”Journal of Virology, 62(5) :1486-1494 (1988).
Fuller, A.O., et al., “Neutralizing Antibodies Specific for Glycoprotein H of Herpes Simplex Virus Permit Viral Attachment to Cells but Prevent Penetration.”Journal of Virology, 63(8) :3435-3443 (1989).
DeLuca, N.A., et al., “Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4.”Journal of Virology, 56(2) :558-570 (1985).
Johnson, D.C., et al., “Herpes Simplex Viruses Lacking Glycoprotein D are Unable to Inhibit Virus Penetration: Quantitative Evidence for Virus-Specific Cell Surface Receptors.”Journal of Virology, 62(12) :4605-4612 (1988).
Desai, P.J., et al., “Excretion of Non-Infectious Virus Particles Lacking Glycoprotein H by a Temperature-Sensitive Mutant of Herpes Simplex Virus Type 1: Evidence that gH is Essential for Virion Infectivity.”J. Gen. Virol., 69:1147-1156 (1988).
Luytjes, W., et al., “Amplification, Expression, and Packaging of a Foreign Gene by Influenza Virus.”Cell, 59:1107-1113 (1989).
Buller, R.M.L., et al., Deletion of the Vaccinia Virus Growth Factor Gene Reduces Virus Virulence,Journal of Virology, 62(3) :866-874 (1988).
Eliot, M., et al., “Construction of a Defective Adenovirus Vector Expressing the Pseudorabies Virus Glycoprotein gp50 and its Use as a Live Vaccine.”Journal of Gen. Virol., 71, 2425-2431 (1990).
Forrester, A., et al., “Construction and Properties of a Mutant of Herpes Simplex Virus Type 1 with Glycoprotein H Coding Sequences Deleted.”Journal of Virology, 66(1) :341-348 (1992).
Ragot, T., et al., “Replication-Defective Recombinant Adenovirus Expressing the Epstein-Barr Virus (EBV) Envelope Glycoprotein gp340/220 Induces Protective Immunity Against EBV-Induced Lymphomas in the Cottontop Tamarin.”Journal of General Virology, 74 :501-507 (1993).
Emi, N., et al., “Pseudotype Formation of Murine Leukemia Virus with the G Protein of Vesicular Stomatitis Virus.”Journal of Virology, 65(3) :1202-1207 (1991).
Dion, M., et al., “Isolation and Preliminary Characterization of Temperature-Sensitive Mutants of Human Cytomegalovirus.”Virology, 158:228-230 (1987).
McGeoch, D.J., “The Genomes of the Human Herpes Viruses: Contants, Relationships, and Evolution.”Ann. Rev. Microbiol., 43:235-265 (1989).
Ensinger, M.J., et al.,

Affiliated with

Also associated with

Rating

Viral vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2809668